Sweetbay

Sweetbay Therapeutics is a preclinical-stage biotechnology company focused on developing transformative therapies for neurological and neurodegenerative disorders. The company's research centers on the Reelin signaling pathway, which plays a critical role in synaptic plasticity and cognitive function. By leveraging insights into Reelin's neuroprotective properties, Sweetbay aims to address the underlying pathology of conditions such as Alzheimer's disease and Angelman syndrome. Their approach includes both protein replacement strategies and small molecule modulators to restore cognitive health. The company was founded as a spin-out from the University of South Florida, utilizing research conducted at the USF Health Byrd Alzheimer's Institute.